Efficacy and safety of deferasirox at low and high iron burdens: Results from the EPIC magnetic resonance imaging substudy

Annals of Hematology

Volumn 92, Issue 2, 2013, Pages 211-219

  Porter, J B ^a   Elalfy, M S ^b   Taher, A T ^c   Aydinok, Y ^d   Chan, L L ^e   Lee, S H ^f   Sutcharitchan, P ^g   Habr, D ^h   Martin, N ^h   El Beshlawy, A ⁱ  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d EGE UNIVERSITY   (Turkey)

^e UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^f INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^g CHULALONGKORN UNIVERSITY   (Thailand)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ CAIRO UNIVERSITY   (Egypt)

Author keywords

Deferasirox; Iron chelation therapy; Iron overload; Liver iron concentration

Indexed keywords

CREATININE; DEFERASIROX; FERRITIN; IRON;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADOLESCENT; ANGIONEUROTIC EDEMA; ARTICLE; CARDIOMYOPATHY; CHILD; CHOLELITHIASIS; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYELID EDEMA; FACE EDEMA; FEMALE; FERRITIN BLOOD LEVEL; FISTULA; GASTROINTESTINAL SYMPTOM; GENERALIZED EDEMA; HEMOSIDEROSIS; HUMAN; IRON BLOOD LEVEL; IRON INTAKE; IRON OVERLOAD; KIDNEY TUBULE DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHRITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SEPSIS; SIDE EFFECT; SYNDROME DELINEATION; THALASSEMIA; URTICARIA; VOMITING;

ADOLESCENT; ADULT; BENZOATES; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; CHOLELITHIASIS; CLINICAL TRIALS, PHASE III AS TOPIC; CREATININE; EDEMA; ETHNIC GROUPS; FEMALE; FERRITINS; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HEPATITIS, VIRAL, HUMAN; HUMANS; INFANT; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; KIDNEY DISEASES; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; THALASSEMIA; TRIAZOLES; YOUNG ADULT;

EID: 84872340568     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1588-x     Document Type: Article

References (21)

1. Loréal O, Deugnier Y, Moirand R, Lauvin L, Guyader D, Jouanolle H, Turlin B, Lescoat G, Brissot P (1992) Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J Hepatol 16:122-127
2. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G (1985) Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 313:1256-1262
3. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G (1996) Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110:1107-1119
4. Olivieri NF, Brittenham GM (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89:739-761
5. Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, Taher AT (2011) Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica 96:1605-1612
6. Olivieri NF (2001) Progression of iron overload in sickle cell disease. Semin Hematol 38(Suppl 1):57-62
7. Olivieri NF (1999) The β-thalassemias. N Engl J Med 341:99-109
8. Thalassaemia International Federation (2008) Guidelines for the clinical management of thalassaemia, 2nd revised edn. Available at http://www. thalassaemia.org.cy/pdf/Guidelines-2nd-revised-edition-EN.pdf
9. Porter JB (2001) Practical management of iron overload. Br J Haematol 115:239-252
10. Brittenham GM (2011) Iron-chelating therapy for transfusional iron overload. N Engl J Med 364:146-156
11. Cappellini MD, Porter JB, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C et al (2010) Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica 95:557-566
12. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S et al (2011) Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5years' follow-up. Blood 118:884-893
13. Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, Kriemler-Krahn U, El-Ali A, Roubert B, El-Beshlawy A (2011) Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-year follow-up from the ESCALATOR study in patients with beta-thalassaemia. Eur J Haematol 87:355-365
14. Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C et al (2011) Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 154:387-397
15. Grosse R, Jarisch A, Yamamura J, Janka G, Nielsen P, Fischer R (2011) Safe and efficient chelation by deferasirox in thalassemia major patients with low liver iron concentrations. Haematologica 96(Suppl 2):abst 0159
16. Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, Kriemler-Krahn U, Roubert B, El-Beshlawy A (2011) Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with beta-thalassaemia: results from the ESCALATOR study. Eur J Haematol 87:349-354
17. St Pierre TG, Clark PR, Chua-anusorn W (2004) Single spin-echo proton transverse relaxometry of iron-loaded liver. NMR Biomed 17:446-458
18. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R et al (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 107:3455-3462
19. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Soulières D, Gattermann N, Tchernia G et al (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 80:168-176
20. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL et al (2007) A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136:501-508
21. Viprakasit V, Ibrahim H, Ha SY, Ho PJ, Li CK, Chan LL, Chiu CF, Sutcharitchan P, Habr D, Domokos G, Roubert B, Xue HL et al (2011) Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. Int J Hematol 93:319-328